INVOKANA(canagliflozin)

Type 2 diabetes; cardiovascular risk reduction in type 2 diabetes with established CVD; diabetic kidney disease (DKD).

1 DTP program
From $225/mo
1 platform

FDA-Approved Indications

Adjunct to diet and exercise for glycemic control in adults with type 2 diabetesReduce risk of ESKD, doubling of SCr, CV death, and HF hospitalization in type 2 diabetes with diabetic nephropathy

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

Cash-pay (self-pay)

via J&J Direct · Johnson & Johnson

$225/mo

$225/30ct (both 100mg and 300mg). $675/90ct. Insurance not accepted. Prices may change at any time without notice.

Eligibility

US resident (incl. Puerto Rico & U.S. Virgin Islands). Valid prescription required. Open to all insurance statuses. Phone enrollment only: (855) 522-3241 or HCP fax (888) 975-0603.

May purchase at cash price. Cannot submit claims to or seek reimbursement from Medicare, Medicaid, TRICARE, DoD, or VA. Costs do not count toward Part D TrOOP or any deductible.

Visit Program

Last verified: Mar 2026

Not sure which INVOKANA program fits your situation?

Find My Options